Your browser doesn't support javascript.
loading
The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership.
Snyder, Rebecca A; Burtness, Barbara; Cho, May; Del Rivero, Jaydira; Doroshow, Deborah B; Hitchcock, Kathryn E; Kalyan, Aparna; Kim, Christina A; Lukovic, Jelena; Parikh, Aparna R; Sanford, Nina N; Singh, Bhuminder; Shen, Chan; Shroff, Rachna T; Vijayvergia, Namrata; Goodman, Karyn A; Kunz, Pamela L.
Afiliación
  • Snyder RA; Departments of Surgical Oncology and Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Burtness B; Department of Internal Medicine, Section of Medical Oncology, and Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Cho M; Department of Medicine, Division of Hematology/Oncology, University of California, Irvine, Irvine, CA, USA.
  • Del Rivero J; Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Doroshow DB; Department of Medicine, Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Hitchcock KE; Department of Radiation Oncology, University of Florida, Gainesville, FL, USA.
  • Kalyan A; Department of Medicine, Division of Hematology & Oncology and Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
  • Kim CA; Department of Internal Medicine, Section of Medical Oncology and Hematology, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
  • Lukovic J; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network and Department of Radiation Oncology, University of Toronto, ON, Canada.
  • Parikh AR; Massachusetts General Cancer Center, Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Sanford NN; Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Singh B; Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Shen C; Departments of Surgery and Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.
  • Shroff RT; Department of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, Tucson, AZ, USA.
  • Vijayvergia N; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Goodman KA; Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Kunz PL; Department of Internal Medicine, Section of Medical Oncology, and Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
J Natl Cancer Inst ; 115(10): 1132-1138, 2023 10 09.
Article en En | MEDLINE | ID: mdl-37364007
Many multicenter randomized clinical trials in oncology are conducted through the National Clinical Trials Network (NCTN), an organization consisting of 5 cooperative groups. These groups are made up of multidisciplinary investigators who work collaboratively to conduct trials that test novel therapies and establish best practice for cancer care. Unfortunately, disparities in clinical trial leadership are evident. To examine the current state of diversity, equity, and inclusion across the NCTN, an independent NCTN Task Force for Diversity in Gastrointestinal Oncology was established in 2021, the efforts of which serve as the platform for this commentary. The task force sought to assess existing data on demographics and policies across NCTN groups. Differences in infrastructure and policies were identified across groups as well as a general lack of data regarding the composition of group membership and leadership. In the context of growing momentum around diversity, equity, and inclusion in cancer research, the National Cancer Institute established the Equity and Inclusion Program, which is working to establish benchmark data regarding diversity of representation within the NCTN groups. Pending these data, additional efforts are recommended to address diversity within the NCTN, including standardizing membership, leadership, and publication processes; ensuring diversity of representation across scientific and steering committees; and providing mentorship and training opportunities for women and individuals from underrepresented groups. Intentional and focused efforts are necessary to ensure diversity in clinical trial leadership and to encourage design of trials that are inclusive and representative of the broad population of patients with cancer in the United States.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Liderazgo / Neoplasias Tipo de estudio: Clinical_trials / Guideline Aspecto: Equity_inequality Límite: Female / Humans País/Región como asunto: America do norte Idioma: En Revista: J Natl Cancer Inst Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Liderazgo / Neoplasias Tipo de estudio: Clinical_trials / Guideline Aspecto: Equity_inequality Límite: Female / Humans País/Región como asunto: America do norte Idioma: En Revista: J Natl Cancer Inst Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos